BioSpace News Archive

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, announces the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.

Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.

Cantargia The shareholders of Cantargia AB are invited to the annual general meeting on Thursday, 23 May 2024, at 15.00 CEST at Ideon Gateway, Scheelevägen 27, Lund, Sweden.

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.

Smith+Nephew, the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal, that shows a novel mechanism of action relating to pressure injury prevention.

SpringWorks Therapeutics, Inc. today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates.

Ocular Therapeutix, Inc. today announced positive topline results from the Phase 1 HELIOS study evaluating AXPAXLI versus a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (‘NPDR’, NCT05695417) without diabetic macular edema (DME). Ocular plans to present the study results at an upcoming meeting.

Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit.

Chemomab Therapeutics Ltd. today announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis (SSc).